Avenue Therapeutics (ATXI) Stock Price, News & Analysis

Company Overview

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Key Stats

• Today's Range: $1.95 to $2.05
• 50-Day Range: $1.89 to $2.81
• 52-Week Range: $1.60 to $26.47
• Volume: 19,269 shs
• Average Volume: 53,458 shs
• Market Capitalization: $3.84 million
• P/E Ratio: 0.11
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Avenue Therapeutics Stock Analysis - MarketRank™

Avenue Therapeutics scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Avenue Therapeutics.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Avenue Therapeutics is 0.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.44.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avenue Therapeutics is 0.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.57.

Price to Book Value per Share Ratio

Avenue Therapeutics has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.74% of the float of Avenue Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Avenue Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avenue Therapeutics has recently increased by 85.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avenue Therapeutics does not currently pay a dividend.

Dividend Growth

Avenue Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.99

Percentage of Shares Shorted

3.74% of the float of Avenue Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Avenue Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avenue Therapeutics has recently increased by 85.77%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.5 / 5
• News Sentiment: -1.06

News Sentiment

Avenue Therapeutics has a news sentiment score of -1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Avenue Therapeutics this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for ATXI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Avenue Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137.00 in company stock.

Percentage Held by Insiders

Only 1.80% of the stock of Avenue Therapeutics is held by insiders.

Percentage Held by Institutions

Only 17.34% of the stock of Avenue Therapeutics is held by institutions.

ATXI Stock Analysis - Frequently Asked Questions

How have ATXI shares performed this year?

Avenue Therapeutics' stock was trading at $12.0750 at the beginning of the year. Since then, ATXI stock has decreased by 83.4% and is now trading at $2.01.
View the best growth stocks for 2024 here.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) announced its earnings results on Friday, August, 9th. The company reported ($6.43) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $5.38.

When did Avenue Therapeutics' stock split?

Shares of Avenue Therapeutics reverse split before market open on Friday, April 26th 2024. The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did Avenue Therapeutics IPO?

Avenue Therapeutics (ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

Who are Avenue Therapeutics' major shareholders?

Top institutional investors of Avenue Therapeutics include Moss Adams Wealth Advisors LLC (1.17%). Insiders that own company stock include Fortress Biotech, Inc, Lindsay A Md Rosenwald, Jay D Kranzler and Invagen Pharmaceuticals, Inc.
View institutional ownership trends.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Avenue Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), General Electric (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATXI
• CUSIP: N/A
• CIK: 1644963
• Web: www.avenuetx.com
• Phone: (781) 652-4500
• Fax: N/A
• Employees: 4
• Year Founded: 2015

Profitability

• EPS (Most Recent Fiscal Year): $18.3550
• Trailing P/E Ratio: 0.11
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,380,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -471.57%
• Return on Assets: -296.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.70
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.86 per share
• Price / Book: 2.34

Miscellaneous

• Outstanding Shares: 1,910,000
• Free Float: 1,878,000
• Market Cap: $3.84 million
• Optionable: Not Optionable
• Beta: -0.17